Study record · Semax
Semax in the acute period of hemispheric ischemic stroke
Semax added to intensive therapy was reported to accelerate regression of neurological deficits, especially motor impairment.
Key result
Semax added to intensive therapy was reported to accelerate regression of neurological deficits, especially motor impairment.
Study details
Study designControlled comparative clinical study
PopulationPatients with acute hemispheric ischemic stroke
Sample sizeNot stated in search extract
RouteClinical Semax formulation
Regimen / exposureDaily doses reported as 12 mg for moderate stroke and 18 mg for severe stroke
Duration5-10 days
ComparatorCombined intensive therapy without Semax
Primary endpoint / questionNeurological functional recovery and electrophysiologic measures
Safety resultModern systematic safety reporting was limited.
Key limitationsOlder regional controlled study; methods and endpoints are not described to contemporary trial-reporting standards in the accessible abstract.
Registry / identifierPMID 11517472